Background Inflammation biomarkers have been introduced into clinical practice for risk-
rating in treatment of patients with cancer. We aimed to confirm the prognostic role of platelet …

Context This review focuses on risk assessment and prediction tools for bladder cancer
(BCa). Objective To review the current knowledge on risk assessment and prediction tools to …

Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic
muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of …

Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …

Abstract Context The European Association of Urology (EAU) guidelines panel on Muscle-
invasive and Metastatic bladder cancer (BCa) updates its guidelines yearly. This updated …

CONTEXT: New guidelines of the International Consultation on Urological Diseases for the
treatment of muscle-invasive bladder cancer (MIBC) have recently been published …

Background Pretreatment neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic
inflammation that has been associated with adverse survival in a variety of malignancies …

Transitional cell (urothelial) carcinoma of the bladder is the second most common urologic
malignancy and is one of the best understood neoplasms, with relatively well-defined …

Purpose: We evaluated the association of soft tissue surgical margins with characteristics
and outcomes of patients treated with radical cystectomy for urothelial carcinoma of the …

CONTEXT: Follow-up of patients treated for bladder cancer (BCa) is of great importance for
both non–muscle-invasive BCa (NMIBC) and muscle-invasive BCa (MIBC) because of the …